Curevo Secures $110 Million to Accelerate Shingles Vaccine Development

New funding and a leadership team pave the way for improved shingles prevention. Curevo, a biotechnology company focused on shingles vaccine development, has successfully secured $110 million in funding. This financial milestone enhances the company’s ability to advance its research and bring more effective vaccine solutions to market. Alongside the funding, Curevo has reinforced its leadership team by adding experienced biotech industry professionals to its board. These strategic moves position the company for significant progress in the competitive vaccine sector. Addressing the Need for